`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`
`Page 1 of 1
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and TrademarkOffice
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`BIB DATA SHEET
`
`15/998,868
`
`FILINGor. 371(c)
`08/1 7/2018
`
`RULE
`
`APPLICANTS
`RHODES PHARMACEUTICALSL.P., COVENTRY, RI;
`
`GROUPARTUNIT ATTORNEY DOCKET
`41861.2700007/JMC/MSR
`
`INVENTORS
`Alexander Oksche, Limburg, GERMANY;
`William Heath, Cambridge, UNITED KINGDOM;
`Timothy Holden, Cambridge, UNITED KINGDOM;
`Derek A. Prater, Cambridge, UNITED KINGDOM;
`Richard S. Sackler, Greenwich, CT;
`Malcolm Walden, Cambridge, UNITED KINGDOM;
`** CONTINUING DATA *8*888888eReREee
`This application is a CON of 15/708,991 09/19/2017 ABN
`which is a DIV of 15/135,794 04/22/2016 PAT 9861628
`which is a CON of 14/800,270 07/15/2015 PAT 9370512
`which is a DIV of 12/489,410 11/09/2009 PAT 9101625
`which is a 371 of PCT/EP2007/058978 08/29/2007
`
`CONFIRMATION NO. 7842 SERIAL NUMBER
`
`aK FOREIGN APPLICATIONS KEKEEKEKEEKEEREKEEREEEEEEEEER
`EUROPEAN PATENT OFFICE (EPO) 06119839.6 08/30/2006
`
`** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **
`09/10/2018
`
`
`
`Foreign Priority claimed STATEOR|SHEETS(4 ves LU No TOTAL |INDEPENDENT
`
`
`
`
`
`
`35 USC 119(a-d) conditions met KA Yes No|LJ Metafter| |DRAWINGS|CLAIMSCOUNTRY CLAIMS
`Verified and
`/CRAIG RICCI/
`Acknowledged
`Examiner's Signature
`Initials
`G ERMANY
`0
`14
`1
`
`ADDRESS
`
`STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
`1100 NEW YORK AVENUE NW
`WASHINGTON, DC 20005
`UNITED STATES
`
`Buprenorphine-wafer for drug substitution therapy
`
`FILING FEE FEES: Authority has been given in Paper
`RECEIVED |No._s—————sésto. Chlarge/credit DEPOSIT ACCOUNT
`for following:
`
`
`
`BIB (Rev. 05/07).
`
`